MedTrace Logo

Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease

NCT00367913 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2006-08-23

No results posted yet for this study

Summary

To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.

Conditions

  • Pulmonary Diseases

Interventions

DRUG

Addition of clarithromycin to rifampicin and ethambutol

DRUG

Addition of Ciprofloxacin to rifampicin and ethambutol

BIOLOGICAL

Vaccination with M.vaccae

Sponsors & Collaborators

  • British Thoracic Society

    lead OTHER

Principal Investigators

  • Ian Campbell, BSc MD FRCP · British Thoracic Society, Research Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-31
Completion
2004-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367913 on ClinicalTrials.gov